Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

Bulletin du cancer - 1 Sept 2015

Brosseau Solenn, Viala Marie, Varga Andréa, Planchard David, Besse Benjamin, Soria Jean-Charles

Abstract excerpt

Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However, all patients showed a tumor progression of 10 to 16 months after the onset of TKI therapy related to molecular resistance mechanisms as T790M mutation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 26235419
DOI: 10.1016/j.bulcan.2015.05.001

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].PMID 26235419Read ↗

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.Semantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.Semantic proximity Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)Semantic proximity Read ↗

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.